More importantly for those focusing on IBB right here, right now, the aforementioned earning report will arrive with the IBB in the midst of a solid stretch of performance.
Quiet as it has been kept, IBB is up 5.3% since April 15. Throw in Monday’s 1.2% gain and that jumps to a 6.5% gain in just over two weeks. Over the past week, investors have poured nearly $246 million into IBB.
iShares Nasdaq Biotechnology ETF
ETF Trends editorial team contributed to this post.